-- Sir Charles Gairdner Hospital
SUNNYVALE, Calif. - Accuray Incorporated (http://www.accuray.com) (Nasdaq: ARAY) announced today that Sir Charles Gairdner Hospital in Perth is the first center in Australia to treat a patient with the CyberKnife® M6™ System (http://www.accuray.com/solutions/treatment-delivery/cyberknife-treatment-delivery/m6-series), the most advanced robotic radiosurgery system in the world and the latest generation CyberKnife System. The new CyberKnife M6 System was designed to provide clinicians with an enhanced stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) solution that targets tumors non-invasively with precisely delivered, high doses of radiation that spare healthy tissue and minimize disruption to patients' lives.
The CyberKnife M6 System (http://www.accuray.com/solutions/treatment-delivery/cyberknife-treatment-delivery/m6-series) is a non-surgical option for many patients who have inoperable or surgically complex tumors, or who seek an alternative to surgery. In addition to the unmatched clinical capabilities of the previous generation CyberKnife Systems, afforded by non-isocentric, non-coplanar robotic beam delivery and real-time tracking and automatic correction for tumor motion, the redesigned CyberKnife M6 System can direct beams from a wider angle around the patient and provides a streamlined user interface for treatment delivery. The result is a system that enables the precise radiosurgical treatment of tumors anywhere in the body with minimal radiation exposure to surrounding healthy tissue and organs.
"On April 7, we successfully treated a patient with a brain metastasis with our new CyberKnife M6 System," stated Prof Bydder, Radiation Oncologist, Sir Charles Gairdner Hospital. "The patient found the procedure simple and convenient. He appreciated the lack of a head frame and being able to breathe freely during treatment. Planning for the treatment was straightforward following the training provided by Accuray. Another 25 patients have been treated since and the team is enthusiastic about providing this treatment to more patients in the future."
On April 23, the CyberKnife M6 System was officially unveiled by Western Australian Minister for Health, Dr. Kim Hames, who informed journalists that the CyberKnife System enables doctors to treat tumours with pinpoint accuracy.
"It is particularly beneficial for the treatment of certain lung, brain, spine, liver and prostate cancers which otherwise may be inoperable, or where other treatment options may compromise other vital organs," stated Dr. Hames. "Another advantage is its ability to treat tumours that move, such as those in the lungs, with sub-millimeter accuracy, which is something other technology is not able to do."
Along with senior representatives from Accuray, the WA Health Acting Director General, Professor Bryant Stokes, Acting Chief Executive of North Metropolitan Health Service, Dr. Peter Wynn Owen and Acting Executive Director of Sir Charles Gairdner Hospital, Dr. Victor Cheng were also in attendance at the launch.
"Accuray developed the CyberKnife M6 Series to meet the needs of every radiation oncology practice with efficient, accurate and flexible treatment options applicable to a wide variety of patients," said Joshua H. Levine, president and chief executive officer of Accuray. "On the heels of adoption in Europe, we are pleased to be working with Sir Charles Gairdner Hospital in Australia, where patients can now have the CyberKnife System as a radiation treatment option."
Sir Charles Gairdner Hospital (SCGH) is one of Australia's leading tertiary hospitals. The hospital has over 600 beds and employs approximately 5500 staff who treat over 420,000 patients every year.
The construction of an expanded Sir Charles Hospital Cancer Center had made the patient journey more convenient with cancer services now located in one building. The new center consolidated Radiation Oncology, Medical Oncology, Haematology, Outpatient Palliative Care, Solaris Care (complimentary therapies). The new Cancer center features with the latest diagnostic and treatment technologies, including the new CyberKnife M6 System.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com